R. LaDuane Clifton served as Chief Financial Officer and Treasurer at Zevra Therapeutics Inc., a clinical-stage rare disease therapeutics company, where he led the finance organization through key periods of growth and transition. In this role, he oversaw financial planning, reporting, treasury operations, and investor relations, playing a critical part in securing financing, optimizing capital allocation, and ensuring robust SEC compliance. His strategic oversight supported Zevra's advancement of pipeline assets and commercial initiatives, contributing to the company's evolution from clinical development to market readiness. Prior to Zevra, Mr. Clifton held senior finance leadership positions in the biopharmaceutical sector. He was Chief Financial Officer at Strongbridge Biopharma plc, managing financial strategy during its Nasdaq listing and subsequent business combination with Xeris Pharmaceuticals. Earlier, as Senior Vice President of Finance and Treasurer at Axogen, Inc., he directed financial operations, risk management, and capital markets activities. His career also includes progressive roles at Endo International plc and Auxilium Pharmaceuticals, Inc., where he handled mergers, acquisitions, and financial integrations following Auxilium's acquisition by Endo. A Certified Public Accountant with more than 25 years of experience, Mr. Clifton began his career at PricewaterhouseCoopers LLP, gaining deep expertise in audit, advisory services, and life sciences accounting. His achievements include guiding multiple public companies through IPOs, debt financings, and strategic transactions, establishing him as a seasoned financial executive adept at driving value in dynamic biotech environments.